Our findings also suggest a potentially beneficial treatment profile with lipophilic statins, possibly via LFA-1 inhibition, as well as adding to the speculation of the potential therapeutic role of direct LFA-1 I domain inhibitors in the management of pulmonary fibrosis. This evidence concerns the gene ITGB2 and pulmonary fibrosis.